Pablo Umaña

Fondatore presso Roche Glycart AG

Health Technology

Profilo

Pablo Umaña is the founder of Roche Glycart AG, which was founded in 2000.
He held the title of Research Director at the time of founding.
Additionally, he worked as Head-Cancer Immunotherapy Discovery at Roche Holding AG in a former position.

Posizioni attive di Pablo Umaña

Società	Posizione	Inizio
Roche Glycart AG Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.	Fondatore	01/09/2000

Tutte le posizioni attive di Pablo Umaña

Precedenti posizioni note di Pablo Umaña

Società	Posizione	Fine
ROCHE HOLDING AG	Corporate Officer/Principal	-

Vedi nel dettaglio l'esperienza di Pablo Umaña

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Pablo Umaña

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
ROCHE HOLDING AG	Health Technology

Aziende private	1
Roche Glycart AG Roche Glycart AG Pharmaceuticals: MajorHealth Technology Roche Glycart AG discovers and develops drugs. It is active in the research and development of new potent antibody-based products for the treatment of unmet clinical needs such as cancer. It uses its proprietary set of technologies to endow therapeutic antibodies. The company has developed glycoengineering technology (GlycoMAb) to boost a natural mechanism of action of therapeutic antibodies developed to mediate target cell killing. The company was founded in 2000 and is headquartered in Zurich, Switzerland.	Health Technology